J Radiat Oncol (2017) 6:247–253 DOI 10.1007/s13566-016-0289-9 ORIGINAL RESEARCH Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control 1,2 1 1 1 John Bowers & Nathan R. Bennion & Martin Richardson & Kelly Spencer & 3 1,3 James Larner & Ronald Kersh Received: 12 September 2016 /Accepted: 2 November 2016 /Published online: 26 November 2016 Springer-Verlag Berlin Heidelberg 2016 Abstract Eleven patients failed locally giving a 2-year actuarial local Purpose/objectives Stereotactic body radiation therapy for control rate of 80.7%, with control rates of 82.5 and 79.2% for centrally located lung tumors has been associated with in- primary and recurrent tumors, respectively (p =0.828). creased risk of toxicity. A current study aims to evaluate tumor Regional control at 2 years was not significantly different for control and toxicity in large cohort of centrally located lesions. primary (72.6%) and recurrent (62.7%). Analysis of toxicity Methods Central location was defined as tumors within 2 cm revealed no grade 4 or 5 events. One grade 3 event was re- of the bronchial tree, trachea, major vessels, esophagus, heart, ported as pneumonitis. Grade 2 toxicity occurred in 10 pa- pericardium, brachial
Journal of Radiation Oncology – Springer Journals
Published: Nov 26, 2016
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera